Published in:
01-11-2020 | SARS-CoV-2 | Short Commentary
First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease
Authors:
Renan Barros Domingues, Maria Cássia Mendes-Correa, Fernando Brunale Vilela de Moura Leite, Ester Cerdeira Sabino, Diego Zanotti Salarini, Ingra Claro, Daniel Wagner Santos, Jaqueline Goes de Jesus, Noely Evangelista Ferreira, Camila Malta Romano, Carlos Augusto Senne Soares
Published in:
Journal of Neurology
|
Issue 11/2020
Login to get access
Abstract
The association between coronaviruses and central nervous system (CNS) demyelinating lesions has been previously shown. However, no case has been described of an association between the novel coronavirus (SARS-COV-2) and CNS demyelinating disease so far. SARS-COV-2 was previously detected in cerebrospinal fluid (CSF) sample of a patient with encephalitis. However, the virus identity was not confirmed by deep sequencing of SARS-COV-2 detected in the CSF. Here, we report a case of a patient with mild respiratory symptoms and neurological manifestations compatible with clinically isolated syndrome. The viral genome of SARS-COV-2 was detected and sequenced in CSF with 99.74–100% similarity between the patient virus and worldwide sequences. This report suggests a possible association of SARS-COV-2 infection with neurological symptoms of demyelinating disease, even in the absence of relevant upper respiratory tract infection signs.